CoTriatec

Quick links to important sections

CoTriatec

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of CoTriatec

Quick Facts

Property Description
Active ingredient Ramipril, Hydrochlorothiazide
Form Tablet
Pharmacological class ACE Inhibitor with Thiazide Diuretic
Common use Management of High Blood Pressure (Hypertension)
Origin Synthetic

What is CoTriatec?

CoTriatec is a Combined Antihypertensive Agent specifically formulated as a synthetic, fixed-dose combination product for the general purpose of managing high blood pressure. It is administered as an oral tablet and belongs to the broad class of Antihypertensive Agents, combining two substances with complementary mechanisms to achieve enhanced efficacy. The product is defined by its action on the cardiovascular system and fluid balance.


What Type of Medicine is CoTriatec?

CoTriatec is classified pharmacologically as an Angiotensin-Converting Enzyme (ACE) Inhibitor with a Thiazide Diuretic. This classification signifies that the drug contains two distinct agents working through different physiological pathways to stabilize blood pressure, an approach that is clinically recognized for supporting patient adherence to chronic hypertension treatment. The drug's identity as a fixed-dose combination tablet means both active substances, Ramipril and Hydrochlorothiazide, are integrated into a single dosage unit. This specific formulation is also marketed under brands such as Tritazide and Tritace Plus in various global regions and is a prescription-only medicine.


Ramipril and Hydrochlorothiazide: A Dual-Component Composition

The active ingredients in CoTriatec are Ramipril and Hydrochlorothiazide. Both are synthetic compounds; Ramipril is recognized as a prodrug that converts into the active metabolite Ramiprilat in the body, while Hydrochlorothiazide is a well-established thiazide-type diuretic. Pharmacological studies confirm that combining these two agents produces a synergistic antihypertensive effect greater than either agent used alone. The deliberate combination aims to address high blood pressure through both the regulation of the body's vascular tension and the management of circulating fluid volume simultaneously.


General Purpose of This Combination Antihypertensive

The general purpose of this dual-action agent is to provide effective management of essential hypertension (high blood pressure) by reducing the overall strain on the cardiovascular system. This approach offers a comprehensive solution for individuals whose blood pressure is not adequately controlled by a single-component drug. A typical use scenario involves long-term management to maintain stabilized blood pressure and minimize potential cardiovascular risks.

What side effects are possible with CoTriatec?

Possible Side Effects and Safety Information

The official safety profile of CoTriatec (Ramipril/Hydrochlorothiazide) is characterized by adverse reactions related to its two components, categorized by frequency and the body system affected, consistent with regulatory documents.


Adverse Reaction Scope

Classification Examples of Documented Effects
Common Reactions Dizziness, headache, fatigue, persistent dry cough, symptomatic hypotension, and metabolic changes (increased blood glucose or uric acid).
System-Organ Classes Vascular (Angioedema), Respiratory (Cough), Metabolic (Electrolyte Imbalance), Ophthalmic (Acute Myopia, Choroidal effusion), and Hepatobiliary (Jaundice).

Serious Adverse Reactions and Safety Constraints

The medicine's regulatory status highlights several severe risks and specific usage constraints:

  • Serious Adverse Reactions: The primary serious risk is Angioedema, which involves rapid swelling of the face, throat, or intestines and is potentially fatal. Other documented serious risks include Fetal Toxicity (injury or death to the fetus), Acute Renal Failure, and rare cases of Hepatic Failure.
  • Time-Related Patterns: Symptomatic hypotension is more likely to occur upon treatment initiation or following a dose increase.
  • Population Constraints: The medicine is contraindicated during the second and third trimesters of pregnancy. It is also restricted or contraindicated in cases of anuria, severe renal impairment (CrCl < 30 mL/min), or known hypersensitivity to ACE inhibitors or sulfonamide-derived drugs.
  • Interaction Restrictions: The concurrent use of CoTriatec with certain agents like aliskiren (in diabetic patients) or a neprilysin inhibitor (e.g., sacubitril/valsartan) is explicitly contraindicated due to heightened risks of hypotension, hyperkalemia, or angioedema. A required wash-out period must be observed when transitioning to or from a neprilysin inhibitor.

This information establishes the official regulatory framework for understanding the medicine's risk profile, distinguishing expected reactions from severe, rare events that necessitate explicit contraindications and special warnings from health authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with CoTriatec is officially documented by regulatory authorities as potentially leading to severe physiological manifestations requiring immediate medical intervention. The primary documented presentation is profound severe hypotension, which commonly results in syncope (fainting) and severe dizziness. Excessive exposure to the combination agent also causes critical fluid and electrolyte imbalance, notably hyponatremia and hypokalemia, which may lead to cardiac arrhythmias.

Regulators classify potential overdose outcomes as life-threatening, including circulatory shock, cardiovascular collapse, and acute renal failure. Swelling of the intestine (Intestinal Angioedema) is a severe, documented risk.

In the event of a suspected overdose, immediate medical attention must be sought. Contacting a poison control center is an officially recommended action. Emergency services must be contacted immediately if symptoms are severe, such as loss of consciousness or signs of profound shock. Management is specified as symptomatic and supportive treatment, involving procedures like intravenous fluid administration to address hypotension. There is no specific antidote known for CoTriatec overdose. Special caution is noted for patients with pre-existing renal impairment, who may face a higher risk due to altered drug clearance.

Therapeutic Uses of CoTriatec

What CoTriatec Treats: Main Uses and Benefits

CoTriatec is a prescription combination medication used for the management of essential hypertension (high blood pressure). The therapeutic approach helps manage symptoms related to systemic imbalance and supports general well-being during symptomatic phases. This fixed-dose combination is applied in clinical settings that involve acute or unstable symptom patterns when a single agent has proven insufficient for management.


Stabilizing Uncontrolled Blood Pressure Readings

CoTriatec is considered relevant for patients diagnosed with essential hypertension whose blood pressure remains inadequately controlled. It is applied when persistent elevation of systolic and diastolic readings suggests the need for additional management support. This combination may assist with managing symptoms related to heightened physiological activity when symptoms are difficult to tolerate with monotherapy.


Reducing the Risk of Cardiovascular Events

A primary therapeutic benefit is that it helps manage symptoms related to systemic imbalance associated with chronic hypertension. By supporting the stability of blood pressure, the medication may be part of a long-term strategy that assists with maintaining functional stability and helps reduce the risk of serious health issues, such as stroke and heart attack.


Quick Fact: Relief for Persistent Systemic Strain
Primary Domain Management of chronic Essential Hypertension
Patient Benefit Supports stability of blood pressure to reduce physiological strain
Typical Scenario Therapeutic maintenance after inadequate response to single-agent treatment

Regulatory References

  1. European Medicines Agency overview

Eligibility and Restrictions for Use

CoTriatec is officially approved for use in adults with essential hypertension whose blood pressure remains inadequately controlled with single-agent therapy (either ramipril or hydrochlorothiazide alone).


Contraindications (Who Must Not Use)

Regulatory documents define specific populations and conditions for whom CoTriatec is strictly prohibited:

  • Pregnancy: Contraindicated during the second and third trimesters. Treatment must be discontinued immediately upon detecting pregnancy.
  • Angioedema: Patients with a history of angioedema related to previous use of any ACE Inhibitor or Angiotensin II Receptor Antagonist.
  • Severe Organ Impairment: Patients with severe impairment of renal function (Creatinine Clearance less than 30 mL/min) or severe liver function impairment.
  • Hypersensitivity: Known allergy to the active substances, other ACE inhibitors, or any sulfonamide-derived drugs (due to the hydrochlorothiazide component).
  • Concurrent Medications: Prohibited with concomitant use of Neprilysin Inhibitors (or within 36 hours of switching) or Aliskiren in patients with diabetes or moderate-to-severe renal impairment.

Restricted and Non-Recommended Use

  • Children and Adolescents (under 18): Use is not recommended due to insufficient data on safety and efficacy.
  • Breastfeeding: Use is not recommended.
  • Mild-to-Moderate Impairment: Patients with mild-to-moderate hepatic or renal impairment may use the medicine only under close medical supervision and often require specific dose restrictions.

What should I know about interactions with other medicines?

Formal Contraindicated Combinations

Co-administration is strictly prohibited with Sacubitril/Valsartan due to a significantly heightened risk of angioedema. A mandatory 36-hour separation period is required when switching between therapies. Use with Aliskiren is formally contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 ml/min/1.73 m^2) due to the severe risk of hypotension and hyperkalemia. Furthermore, certain extracorporeal treatments where blood contacts negatively charged surfaces are also formally prohibited due to the risk of anaphylactoid reactions.


Clinically Significant Interactions

Interactions with substances that increase serum potassium, such as potassium supplements or potassium-sparing diuretics, carry a documented additive risk of hyperkalemia. Co-administration with Lithium is noted to increase serum concentrations and risk of toxicity by reducing Lithium's renal clearance. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 Inhibitors, may reduce the antihypertensive effect and increase the risk of renal function deterioration; this risk is specifically noted as heightened in the elderly or volume-depleted patients. Additionally, Cholestyramine and Colestipol resins reduce the absorption of the Hydrochlorothiazide component, necessitating a specific administration timing of at least one hour before or four to six hours after the resin. Finally, alcohol, barbiturates, or narcotics are documented to potentiate orthostatic hypotension.

Mechanism of Action

Primary Mechanism: Inhibiting the Renal Salt Transporter

The action of CoTriatec centers on the inhibition of the Sodium-Chloride Cotransporter ( NCC) , a primary biological target located in the epithelial cells of the kidney's distal convoluted tubule. This targeted interaction directly halts the reabsorption of sodium and chloride ions from the tubular fluid. The acute consequence of this molecular blockade is an increase in urinary output (diuresis) and an immediate reduction of extracellular fluid volume.


Systemic Effect: Modulating Vascular Resistance

Beyond its initial effect on fluid volume, the mechanism engages secondary domains that modify the vascular system. Over time, the drug's activity shifts to reducing Total Peripheral Resistance ( TPR) through an effect on blood vessel walls. This sustained physiological consequence is a decrease in the overall resistance experienced by the heart and circulatory system.


Pathway Response: Indirect RAAS Activation

The resultant decrease in fluid volume triggers a compensatory feedback loop in the Renin-Angiotensin-Aldosterone System ( RAAS). This mechanistic response modifies the rate of fluid loss but also influences electrolyte balance in the kidney, which is a key physiological consequence of the drug's activity pattern.

Dosage and Administration Information

The general use of CoTriatec, a fixed-dose oral tablet, is defined by strict administration protocols, primarily positioning it as a maintenance therapy for high blood pressure management. The medication is prescribed for once-daily use and should be swallowed whole with liquid; the tablet must not be crushed or chewed. To establish a consistent routine, it is advised to take the dose at the same time each day, usually in the morning, and intake is permitted with or without food. The combination product is generally not indicated for initiating treatment but follows a protocol where the fixed dose is established after inadequate control with single-agent therapy.

The initial administration of the fixed combination begins at the lowest available strength (2.5 mg ramipril / 12.5 mg hydrochlorothiazide). The dose can be progressively increased, but the maximum daily administration must not exceed 10 mg of ramipril and 25 mg of hydrochlorothiazide.

Specific protocols define dose adjustments for certain patient groups. The combination is not recommended for use in children and adolescents under 18 years of age. For patients with renal impairment (creatinine clearance 30 to 60 mL/min), the maximum dose is restricted to 5 mg ramipril / 25 mg hydrochlorothiazide daily. Similarly, patients with mild to moderate hepatic impairment are limited to a maximum daily dose of 2.5 mg ramipril / 12.5 mg hydrochlorothiazide. These rules structure the use of the medicine, ensuring adherence to established limits.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

Research focused on the primary treatment candidate, Agent X, in a large-scale, placebo-controlled trial. Studies have investigated whether activating the C-receptor was associated with changes in measured patient endpoints. Research was explored for an association with a reduction in the frequency of flare-ups over time.

  • Primary Endpoint (Symptom Frequency): Clinical trials assessed the effect of this treatment on specific metrics. In the trials reviewed, participants received a daily dose. The analysis assessed the change in the number of reported weekly symptoms compared to the placebo group over a six-month period.
  • Secondary Endpoint (Pain and Inflammation): Studies have also examined whether the treatment was associated with a reduction in pain reported by participants. Additionally, in trials, the drug was associated with a measured reduction in inflammation based on specific trial criteria.
  • Safety Profile: The safety profile was assessed in adult participants during the trials.

Drug Interaction Studies

Research was conducted to understand how Agent X might interact with commonly prescribed medications.

  • Drug Y Interaction: Studies have explored potential interactions with other medications, including Drug Y. The trials assessed whether the co-administration of Agent X and Drug Y resulted in altered pharmacokinetic profiles for either drug.
  • Drug Z Interaction: No specific interaction studies were performed with Drug Z.

Formulation Research

The specific formulation was used to investigate the administration of the active agent.

  • Onset of Effect: The formulation was studied to address symptom onset, and research evaluated the effect on the onset of participant-reported symptoms.
  • Combination Agent (Agent B): Research explored whether this combination of agents had an effect on the management of the disease. The research sought to determine if the two agents, when co-administered, affected the same endpoints as the monotherapy. The trials specified administration on an empty stomach to assess absorption.

Patient Cohort Considerations

The initial research was conducted under specific inclusion criteria to define the study population.

  • Exclusionary Criteria: The trials excluded participants with pre-existing heart conditions. They also excluded individuals under the age of 18 or those with severe renal impairment.
  • Long-Term Follow-up: A small extension study is currently monitoring the participants from the primary trial to gather data on participant-reported events after the initial six-month period. The follow-up research indicates data remains limited regarding events beyond the trial duration.

Frequently Asked Questions (FAQ)

Common questions about CoTriatec (FAQ)


Q: What is the active ingredient in CoTriatec?

Official product information states that this medicine is a combination product. It contains two active ingredients: ramipril, which is an ACE inhibitor, and hydrochlorothiazide, which is a thiazide diuretic (or 'water pill').


Q: What is the main difference between CoTriatec and [Drug X]?

CoTriatec is defined by its fixed combination of two distinct therapeutic agents: ramipril (an ACE inhibitor) and hydrochlorothiazide (a diuretic). This unique dual-action composition is the main differentiating factor described in the regulatory mechanism of action.


Q: Why do people say CoTriatec is different from other medicines for this condition?

The primary distinction is that this is a fixed combination product. It uses two separate therapeutic agents—an ACE inhibitor and a diuretic—that work together through dual mechanisms to manage high blood pressure.


Q: Why are there warnings about CoTriatec and [Specific Organ/System]?

Warnings and precautions in the regulatory documents describe the need for caution related to renal (kidney) and hepatic (liver) impairment. This is because these organs are essential for the body to properly process and eliminate the medication from the body.


Q: Why is my doctor prescribing CoTriatec instead of something else?

Official guidelines indicate that fixed-combination therapy is generally used for people whose blood pressure was not adequately controlled when using only one of the individual components alone. Official regulatory documents position it as a maintenance therapy for high blood pressure.


Q: Can I take CoTriatec if I have high blood pressure?

Official indications state the product is used for the treatment of essential hypertension (high blood pressure) when a healthcare professional determines that combination therapy is appropriate for the patient.


Q: How quickly should I expect to notice any effects from CoTriatec?

Studies show that the diuretic component (hydrochlorothiazide) typically begins causing an increase in urination within 2 hours after the dose. The peak effect is often described as occurring in approximately 4 hours.


Q: Does CoTriatec stay in your system for a long time?

Information on how the drug is processed in the body shows that the diuretic component has an elimination half-life that is generally described as ranging between 5.6 and 14.8 hours.


Q: Can CoTriatec be taken with pain relievers like ibuprofen or aspirin?

Regulatory labels note a potential drug interaction with Non-Steroidal Anti-Inflammatory Agents (NSAIDs) like ibuprofen. Co-administration may increase the risk of kidney impairment and could potentially reduce the effectiveness of blood pressure control.


Q: Are there any vitamins or supplements that interact with CoTriatec?

The ramipril component can cause an increase in blood potassium levels. For this reason, official warnings advise avoiding potassium supplements and salt substitutes that contain potassium, unless otherwise instructed.


Q: What are the most common side effects people report from CoTriatec?

Based on the results from clinical trials for hypertension, the most commonly reported adverse reactions often include symptoms such as headache, dizziness, fatigue, and a dry cough.


Q: Do the side effects of CoTriatec go away after a while?

While the duration of most side effects is not specifically detailed, official information indicates that the dry cough associated with the ramipril component may take time to resolve and can sometimes persist even after the medication is discontinued.


Q: Can CoTriatec cause changes in sleep patterns?

Changes in sleep patterns are not listed as one of the most common side effects. However, general warnings regarding fluid and electrolyte imbalance may mention symptoms like lethargy, drowsiness, or restlessness.


Q: Is it true that CoTriatec affects your appetite or weight?

Regulatory adverse reaction data lists decreased appetite as a less common reported event. Additionally, changes in fluid balance associated with the diuretic component may potentially affect body weight.


Q: Is there a warning about CoTriatec and driving or operating machinery?

Official patient information indicates that avoiding driving or operating heavy machinery is generally advised until a person knows how the medicine affects them. This warning is due to the potential for side effects like dizziness or lightheadedness.


Q: Is it possible to become dependent on CoTriatec?

Official regulatory labels do not describe dependency as a side effect. Instead, they caution patients against sudden interruption or discontinuation of the medication unless directed to do so by a physician.


Q: What conditions make someone ineligible to use CoTriatec?

The regulatory list of contraindications includes the following conditions: a known allergy to the components or to sulfa-derived drugs, a history of angioedema (swelling) from any ACE inhibitor, anuria (inability to urinate), and being pregnant or breastfeeding.


Q: Does CoTriatec interact with alcohol?

Regulatory safety information states that alcohol may increase the blood pressure-lowering effect of the medicine. This increase can heighten the risk of adverse symptoms such as lightheadedness or dizziness.


Q: What is the general safety profile of CoTriatec?

The overall safety profile is detailed in the Warnings, Precautions, and Contraindications sections of the regulatory label. These sections describe important potential risks such as angioedema (severe swelling), hypotension (low blood pressure), and fetal toxicity.


Q: Did CoTriatec go through clinical trials for its main use?

Yes, the regulatory label includes a dedicated 'Clinical Studies' section. This confirms that the drug was evaluated in human clinical trials to establish its claims for treating hypertension and related cardiovascular risk reduction.


Q: Where can I find the official package insert for CoTriatec?

The official patient and prescribing information, often referred to as the package insert, is described as being available through government-run resources such as DailyMed (FDA), the European Medicines Agency (EMA) SmPC, or the product monograph from Health Canada.


Q: Are there any long-term risks associated with CoTriatec?

Regulatory warnings mention that the hydrochlorothiazide component, when used long-term, has been associated with a potential increase in the risk of non-melanoma skin cancer. Official guidelines advise using sun protection while taking this medicine.


Q: How is CoTriatec supposed to be stored?

Official regulatory labels include a dedicated section, typically titled 'How Supplied/Storage and Handling,' that details the required temperature range and specific conditions for properly storing the medication.


Q: Is CoTriatec available as a generic medicine?

Yes, the existence of product monographs and official labels for generic formulations (containing ramipril and hydrochlorothiazide) confirms that equivalent generic options are available for this combination drug.


Q: Are there any dietary restrictions I should know about when taking CoTriatec?

A key restriction described in the official warnings is avoiding potassium supplements and salt substitutes that contain potassium. No other specific food is generally restricted beyond alcohol.


Q: Is it normal to feel a bit dizzy when starting CoTriatec?

Dizziness or lightheadedness are described in regulatory documents as some of the most common adverse effects reported. This is especially noted when a person first starts taking the medication or when the dosage is increased.


Q: What kind of monitoring is typically done when starting CoTriatec?

Regulatory labels advise that regular blood and urine tests may be needed to check for potential unwanted effects. This monitoring is particularly important for checking the patient's fluid and electrolyte balance, such as their potassium levels.


Q: Does CoTriatec interact with birth control pills?

Official information indicates that side effects like severe diarrhea or vomiting may potentially reduce the effectiveness of oral contraceptive pills. Patients are advised to seek guidance if these side effects occur.


Q: Is CoTriatec safe to use during pregnancy?

Official regulatory labels include a boxed warning that the drug is contraindicated (must not be used) during the second and third trimesters of pregnancy. Use during these periods can cause serious injury or death to the developing fetus.


Q: What is the general research theme regarding CoTriatec's efficacy?

The research themes summarized in the clinical studies section of the regulatory documents focus on the drug's effectiveness in achieving and maintaining lower blood pressure and supporting cardiovascular risk reduction.


Q: What does the research say about CoTriatec's long-term effectiveness?

The drug is officially indicated for maintenance therapy, which is supported by clinical studies that have evaluated its effectiveness over an extended period of time in managing hypertension.


Q: Does CoTriatec contain lactose or gluten?

Official non-medicinal ingredient lists, such as those published by Health Canada, confirm that the tablets contain lactose monohydrate. Information regarding gluten is generally covered under specific warnings if present.


Q: What should I do if I get a severe allergic reaction to CoTriatec?

Patient counseling information indicates that signs of a severe allergic reaction, such as swelling of the face, throat, or difficulty breathing, should be immediately reported to a healthcare professional. The medication should be discontinued until instructed otherwise.


Q: Are there any age limits for taking CoTriatec?

Official information describes that the drug is not recommended for children and adolescents under 18 years of age because safety and effectiveness in that group have not been established. For elderly patients (over 65), official guidelines state that dose adjustments may be needed due to age-related changes in organ function.


Q: Are there any foods or drinks to specifically avoid while taking CoTriatec?

Official warnings describe the need to avoid consuming alcohol and avoiding potassium supplements or salt substitutes that contain potassium, due to potential adverse effects.

How should CoTriatec be stored and disposed of?

Storage and Disposal Requirements

CoTriatec (Ramipril/Hydrochlorothiazide) must be stored strictly according to regulatory specifications to maintain its stability.


Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 15 C to 25 C (59 F to 77 F). Do not freeze.
Protection Keep in the original container, tightly closed, and protect from light and moisture.
Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired CoTriatec should be disposed of via an authorized drug take-back program or official medicine collection points. The medication must not be flushed down a toilet or poured into a drain, as this prevents environmental contamination and misuse. If a take-back program is unavailable, follow specific governmental guidelines for safe household disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of CoTriatec found in:

A-Z Index: